Home | Health News | Themes | Search | Blog | Testimonials | Blood Bank | About Us
 
   
   
   
   
   
   
   
 
testing

 
   
 



Indication & Dosage
 
 
Intravenous
ACUTE LEUKAEMIA
Adult: 1.4 mg/m2 or 25-75 mcg/kg wkly. Max dose: 2 mg wkly.
 
Intravenous
ACUTE LEUKAEMIA
Child: Usual: 1.5-2 mg/m2. <10 kg: starting dose 0.05 mg/kg/wk.
   
Precautions Elderly. Preexisting pulmonary dysfunction or neuromuscular disease; leucopenia or a complicating infection; impaired liver function; obstructive jaundice. Routine prophylactic laxative needed to ensure regular bowel movement. Discontinue immediately if extravasation occurs, and inj any remaining drug into another vein, followed by local Inj of hyaluronidase and topical heat application to the affected area to aid in drug removal and reduce discomfort. Discontinue in patients who develop progressive dyspnea. CBC to be checked before each dose admin. Frequent monitoring of uric acid during first 3-4 wk of treatment and watch out for uric acid nephropathy.
   
Potentially Life-threatening 
Adverse Drug Reactions
Dose limiting neurotoxicity (e.g. motor function impairment, gait abnormalities), hyperuricaemia, bronchospasm, azospermia, amenorrhoea, alopoecia, leucopenia, urinary dysfunction, abdominal cramps, vomiting, diarrhoea, severe constipation, paralytic ileus, convulsions, hypertension, orthostatic hypotension, ptosis, hoarseness, optic neuropathies, hallucinations, blindness, neurological deafness, difficulty in walking, syndrome of inappropriate ADH secretion.
   
Adverse Drug Reactions Myelosuppression
   
Interactions Decreased digoxin (tablets) and verapamil absorption with antineoplastic regimens. Increased etoposide serum levels with vincristine. Increased toxicity when ganciclovir given with, immediately before or after vincristine. Reduced vincristine metabolism with miconazole. Increased neurotoxicity with isoniazid, itraconazole, voriconazole, posaconazole and nifedipine. Decreased immune response when used concurrently with vaccines. Increased myelotoxicity with zidovudine. Increased risk of thromboembolic complications with tamoxifen. Increased risk of ototoxicity with ototoxic drugs (e.g. platinum-containing antineoplastic agents). Possible risk of earlier onset and/or increased severity of adverse effects with macrolides. Possible increase in vincristine levels with aprepitant. Possible decrease in antiepileptic levels with vincristine, monitor serum antiepileptic levels and effectiveness of chemotherapy.
   
   
 

 

SocialTwist Tell-a-Friend
 
 
Home  |   Privacy Policy   |   News Lettter   |   Site Map   |  Disclaimer  |  About Us
   copyright@totalhealthneeds.com   Webmaster:- o3sa.co.in